6-K - I-Mab (0001778016) (Filer)

6-K - I-Mab (0001778016) (Filer)

6-K - I-Mab (0001778016) (Filer)

6-K - I-Mab (0001778016) (Filer)

6-K - I-Mab (0001778016) (Filer)

6-K - I-Mab (0001778016) (Filer)

6-K - I-Mab (0001778016) (Filer)

6-K - I-Mab (0001778016) (Filer)

6-K - I-Mab (0001778016) (Filer)

6-K - I-Mab (0001778016) (Filer)

ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time. The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year fin

Completed divestiture of China operationsUliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody)Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig first-line gastric cancer combination studies (CLDN18.2 X 4-1BB bispecific)Ragistomig presentation at ASCO 2024 highlights encouraging early data (PD-L1 X 4-1BB bispecific)Well-positioned for pipeline advancement with $207.5 million in cash and cash equivalents, and short-term investments as of June 30, 2024, and cash runway expected into 2027I-Mab will hold a conference call and webcast today, August 28th, at 8:00 AM ETROCKVILLE, Md., Aug. 28, 2024 /PRNews

Conference call to discuss financial results and recent business highlights to take place on Wednesday, August 28, 2024, at 8:00 AM ET ROCKVILLE, Md., Aug. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to host a conference call and webcast on Wednesday, August 28, 2024, 8:00 AM ET to discuss financial results, pipeline progress and recent business highlights for the half year ended June 30, 2024.

Significant progress made year-to-date on key clinical assets:‐         Uliledlimab (CD73 antibody): Encouraging early results were presented at ASCO 2023‐         Givastomig (Claudin 18.2 x 4-1BB bispecific antibody): Topline Phase 1 data with promising early efficacy signals, including patients with low levels of Claudin 18.2 tumor expression. Data to be presented at ESMO 2023Eftansomatropin alfa (long-acting recombinant human growth hormone): Phase 3 pivotal study evaluating weekly injection of eftansomatropin alfa met the primary endpoint of annualized height velocity at week 52 and demonstrated non-inferiority to Norditropin®, administered by daily injection. A BLA filing is being plann

ROCKVILLE, Md. and SHANGHAI, Aug. 8, 2023 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ:IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced that it will report business and corporate updates and financial results for the six months ended June 30, 2023, before the market opens on Thursday, August 17, 2023, and host a conference call to discuss the results and provide corporate updates at 8:00 a.m. EST. I-Mab Conference Call Information Investors and analysts are invited t

GAITHERSBURG, Md. and SHANGHAI, China, March 20, 2023 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ:IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will report financial results for the full year ended December 31, 2022 before the market opens on Friday, March 31, 2023, and host a conference call to discuss the results and provide a corporate update at 8:15 a.m. EST. I-Mab Conference Call Information Investors and analysts are invited to join the conference cal

Abstract summarizing lemzoparlimab Phase 2 data selected for proffered paper presentation on September 10Investor conference call scheduled at 8:00 a.m. ET (English) on September 12GAITHERSBURG, Md. and SHANGHAI, China, Sept. 6, 2022 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ:IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the results from its Phase 2 clinical study of lemzoparlimab (also known as TJC4) in combination with azacitidine (AZA) in patients with higher risk myelodysplastic syndrome (HR-MDS) will be featured in a proffered paper presentation at the upcoming European Society

-  Major updates will focus on global clinical development of core assets, upcoming milestones and financial results -  The Company will update on potential implementation of a comprehensive share purchase program by the Company and current shareholders -  Conference Calls Scheduled at 7:00 a.m. ET (Mandarin) and 8:15 a.m. ET (English) GAITHERSBURG, Md. and SHANGHAI, Aug. 19, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (NASDAQ:IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it will report business and corporate updates and financial results for the six months ended June 30, 202

-  Uliledlimab appears safe and well-tolerated as a monotherapy and a combination therapy with toripalimab with no dose limiting toxicity -  Encouraging efficacy signals were observed in a non-small cell lung cancer (NSCLC) patient cohort -  Results indicate CD73 expression correlates with clinical response as a potential predictive biomarker -  Company aims to initiate Phase 3 study in NSCLC in 2023 -  The Company will host investors call on Friday, May 27 at 8 a.m. ET SHANGHAI and GAITHERSBURG, MD., May 26, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq" IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics,

SHANGHAI and GAITHERSBURG, MD., May 19 , 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq" IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will hold a call with investors at 8 a.m. EST on May 27th to present preliminary data from an ongoing phase 2 clinical trial of its differentiated CD73 antibody uliledlimab (also known as TJD5, or TJ004309) and the global clinical development plan. I-Mab Conference Call Information Investors and analysts are invited to join the conf

SC 13G/A - I-Mab (0001778016) (Subject)

SC 13G/A - I-Mab (0001778016) (Subject)

SC 13D - I-Mab (0001778016) (Subject)

SC 13D/A - I-Mab (0001778016) (Subject)

SC 13G/A - I-Mab (0001778016) (Subject)

SC 13G/A - I-Mab (0001778016) (Subject)

SC 13G/A - I-Mab (0001778016) (Subject)

SC 13G/A - I-Mab (0001778016) (Subject)

SC 13G - I-Mab (0001778016) (Subject)

SC 13G - I-Mab (0001778016) (Subject)

Siebert Williams Shank initiated coverage of I-Mab with a rating of Buy and set a new price target of $96.00

Needham reiterated coverage of I-MAB with a rating of Buy and set a new price target of $85.00 from $83.00 previously

HC Wainwright & Co. reiterated coverage of I-MAB with a rating of Buy and set a new price target of $95.00 from $75.00 previously

Cantor Fitzgerald reiterated coverage of I-MAB with a rating of Overweight and set a new price target of $90.00 from $76.00 previously

Daiwa Securities initiated coverage of I-MAB with a rating of Buy

Needham & Company LLC initiated coverage of I-Mab with a rating of Buy

Needham initiated coverage of I-MAB with a rating of Buy and set a new price target of $75.00

HC Wainwright reiterated coverage of I-Mab with a rating of Buy and set a new price target of $75.00 from $55.00 previously

Piper Sandler initiated coverage of I-Mab with a rating of Overweight and set a new price target of $75.00

H.C. Wainwright reiterated coverage of I-MAB with a rating of Buy and set a new price target of $75.00 from $55.00 previously

I-Mab (NASDAQ:IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. Wei Fu as the Chairman of the Board of Directors. He succeeds Dr. Pamela M. Klein, who steps down from I-Mab's Board of Directors and the Interim Chairperson position.  Mr. Wei Fu has served as a member of the I-Mab Board of Directors since June 2018 and is the Chief Executive Officer of CBC Group, a healthcare asset management firm and the founding and largest shareholder of I-Mab. In addition, Mr. Raj Kannan intends to leave his role as Chief Executive Officer and as a member of the Company's Board of Directors, effective July

Gainers ENDRA Life Sciences (NASDAQ:NDRA) stock increased by 71.6% to $0.15 during Wednesday's pre-market session. The company's market cap stands at $1.5 million. Concord Medical Services (NYSE:CCM) stock moved upwards by 29.04% to $2.71. The company's market cap stands at $117.6 million. Barinthus Biotherapeutics (NASDAQ:BRNS) shares increased by 21.69% to $2.3. The market value of their outstanding shares is at $89.7 million. Heart Test Laboratories (NASDAQ:HSCS) stock moved upwards by 12.87% to $5.81. The company's market cap stands at $3.8 million. I-MAB (NASDAQ:IMAB) shares increased by 12.23% to $2.11. The company's market cap stands at $170.6 million. Agenus (NASDAQ:AGEN) stock

The collaboration will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody jointly developed by I-Mab and ABL Bio, with Bristol Myers Squibb's immune checkpoint inhibitor, nivolumab, and chemotherapy, as a potential first-line treatment for patients with advanced Claudin 18.2-positive gastric and esophageal cancers. Under the terms of the agreement, the study will be a multi-national Phase 1 study conducted by I-Mab. Bristol Myers Squibb will supply nivolumab. Nivolumab is an immune checkpoint inhibitor that is designed to block the PD-L1 protein on cancer cells from binding to PD-1, enhancing T-cell function and resulting in improved anti-tum

Gainers Concord Medical Services (NYSE:CCM) shares moved upwards by 51.9% to $1.2 during Tuesday's regular session. The market value of their outstanding shares is at $52.1 million. Annexon (NASDAQ:ANNX) shares increased by 32.96% to $6.09. The company's market cap stands at $562.7 million. Olema Pharmaceuticals (NASDAQ:OLMA) stock moved upwards by 26.7% to $14.9. The company's market cap stands at $833.4 million. Pasithea Therapeutics (NASDAQ:KTTA) shares moved upwards by 22.59% to $7.0. The market value of their outstanding shares is at $7.3 million. Fresh2 Group (NASDAQ:FRES) stock moved upwards by 21.12% to $0.43. The company's market cap stands at $10.5 million. I-MAB (NASDAQ:IMAB

I-MAB's (NYSE:IMAB) short percent of float has risen 113.98% since its last report. The company recently reported that it has 1.30 million shares sold short, which is 3.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.85 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is imp

Needham analyst Gil Blum reiterates I-MAB (NASDAQ:IMAB) with a Buy and maintains $6 price target.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. B of A Securities cut the price target for Li Auto Inc. (NASDAQ:LI) from $60 to $55. B of A Securities analyst Ming Hsun Lee maintained a Buy rating. Li Auto shares gained 2.7% to close at $37.77 on Friday. See how other analysts view this stock. Mizuho boosted the price target for Gulfport Energy Corporation (NYSE:GPOR) from $148 to $166. Mizuho analyst Nitin Kumar maintained a Neutral rating. Gulfport Energy shares rose 1.6% to close at $152.54 on Friday. See how other analysts view this stock.

Piper Sandler analyst Joseph Catanzaro maintains I-MAB (NASDAQ:IMAB) with a Overweight and lowers the price target from $15 to $10.

HC Wainwright & Co. analyst Andrew Fein reiterates I-MAB (NASDAQ:IMAB) with a Buy and lowers the price target from $18 to $8.

Needham analyst Gil Blum maintains I-MAB (NASDAQ:IMAB) with a Buy and lowers the price target from $8 to $6.

ROCKVILLE, Md., Nov. 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that Sean (Xi-Yong) Fu, PhD, MBA has been appointed as the Company's permanent Chief Executive Officer ("CEO") effective November 1, 2024. Dr. Fu has served as Interim CEO since July 15, 2024. Dr. Fu will continue to serve as a member of the Board of Directors of I-Mab. "Sean's appointment serves as a significant step towards further rea

Engagement is part of I-Mab's commitment to transition to a U.S.-based biotech PwC to serve as independent registered public accounting firm for FY 2024 ROCKVILLE, Md., Aug. 7, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) ("I-Mab", the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that the Audit Committee of its Board of Directors has approved the appointment of PricewaterhouseCoopers LLP (U.S.) ("PwC US") as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, effective immediately.

ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical

GAITHERSBURG, Md. and SHANGHAI, June 22, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (NASDAQ:IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced the appointment of Mr. Raj Kannan as the Company's new Chief Executive Officer and a member of the board of directors effective June 22, 2023. This appointment serves as a significant step towards further realizing I-Mab's mission of delivering transformative therapies to patients worldwide. Raj Kannan has over 30 year

- Genexine to focus on global drug development and commercialization - Near term milestones should drive shareholder value - Renewed effort to expand pipeline with an emphasis on novel, differentiated products Genexine (KOSDAQ: 095700) a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, announced the appointment of Neil Warma as its President and Chief Executive Officer. Mr. Warma who has over 25 years of experience as a global entrepreneur, company builder and successful CEO will lead Genexine onto the world stage with a focus on advancing Genexine's key products to market, ex

NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- DDC Enterprise Limited (the "Company" or "DDC"), a digital publisher and merchandising company that owns and operates the brand DayDayCook, and Ace Global Business Acquisition Limited ("Ace") (NASDAQ:ACBA, ACBAU, ACBAW))), a special purpose acquisition company ("SPAC"), announced today that Ace has filed a preliminary proxy statement with the U.S. Securities and Exchange Commission ("SEC") in connection with the previously announced business combination transaction between DDC and Ace . (the "Business Combination"). While the information in the filed preliminary proxy statement is subject to change, it provides important information about Ace's

SHANGHAI and GAITHERSBURG, Md., Nov. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ:IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced the appointment of John Long as the Company's Chief Financial Officer and Jielun Zhu as the Company's Chief Strategy Officer, both effectively immediately. The two appointments will further strengthen the Company's senior executive team, positioning I-Mab well for its transformation into a global biopharma company. John Long will report to

SHANGHAI and GAITHERSBURG, Md., June 21, 2021 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ:IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the appointment of Andrew Zhu, MD, PhD, to the Company's Scientific Advisory Board. "We are delighted to welcome Dr. Zhu to our scientific advisory board," said Dr. Jingwu Zang, Founder and Chairman of I-Mab. "His expertise in the field of gastrointestinal cancers, particularly hepatobiliary cancers, and his influence in the international me

SHANGHAI and GAITHERSBURG, Md., June 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ:IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that Dr. Ruyi He and Professor Rong Shao have been elected as members of the Company's board of directors. Dr. Ruyi He will serve on the compensation committee and Professor Shao will serve on the corporate governance committee both effective June 1, 2021. "We are honored to welcome Dr. He and Professor Shao to our board, and look forward to

TORONTO and CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN); (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the appointment of Neil Warma, MBA, to its Board of Directors with immediate effect. "I am delighted to welcome Neil Warma as a member of the ProMIS Board of Directors at this time," said Eugene Williams, Executive Chairman of ProMIS Neurosciences. "Neil's broad, international experience, coupled with a successful track record of executive leadership is a very welcome addit